Anti-inflammatory effects of locally applied enzyme-loaded ultradeformable vesicles on an acute cutaneous model

Superoxide dismutase (SOD) and catalase (CAT) are active scavengers of reactive oxygen species and were incorporated into ultradeformable vesicles with the aim of increasing enzyme bioavailability (skin delivery). These special very adaptable vesicles have been formulated and optimized for enzyme transport in order to penetrate into or across the intact skin barrier. Anti-inflammatory activity of SOD-loaded, CAT-loaded and of SOD- and CAT-loaded ultradeformable vesicles applied epicutaneously was measured using different protein doses on the skin, on an arachidonic acid-induced mouse ear oedema. The biological anti-oedema activity is a measurement of drug-targeting potentiation in the organ. Delivery by means of deformable vesicles was compared to conventional vesicles or the absence of an enzyme carrier mediated transport. This was done at various times following prophylactic application of the test formulations. Positive reference groups were treated epicutaneously with several low molecular weight non-steroidal anti-inflammatory drugs (NSAIDs). The latter included indomethacin (3 mg kg−1), etofenamate (30 mg kg−1) and piroxicam (1 mg kg−1) and reduced the oedema by 94 ± 4%, 81 ± 4% and 42 ± 5%, respectively, if measured 30 min after ear treatment with a NSAID. Of the enzyme-loaded carriers tested, only the enzyme-loaded ultradeformable vesicles reduced the swelling of ears significantly: SOD (90 µg kg−1), CAT (250 µg kg−1) and SOD (90 µg kg−1) plus CAT (250 µg kg−1) reduced the oedema by 70 ± 12%, 65 ± 10% and 61 ± 19%, respectively, at t = 30 min. Aqueous enzyme solutions and empty carriers had no such effect. The combination of two enzymes resulted in no increased therapeutic effect, but the results are inconclusive since only two dose combinations were tested. The results presented in this study suggest that antioxidant enzymes delivered by means of ultradeformable lipid vesicles can serve as a novel region-specific treatment of inflammation.

[1]  M. Rother,et al.  Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial , 2007, Annals of the rheumatic diseases.

[2]  Gregor Cevc,et al.  Spatial distribution of cutaneous microvasculature and local drug clearance after drug application on the skin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Tsong-Long Hwang,et al.  Liposomes as Vehicles for Enhancing Drug Delivery Via Skin Routes , 2006 .

[4]  Y. Barenholz,et al.  Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD , 2006, Journal of drug targeting.

[5]  Gary P. Martin,et al.  Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects , 2006, Drug delivery.

[6]  G. E. El Maghraby,et al.  Mechanisms of action of novel skin penetration enhancers: phospholipid versus skin lipid liposomes. , 2005, International journal of pharmaceutics.

[7]  M. Cruz,et al.  Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween 80. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  H. Maibach,et al.  Elastic vesicles as topical/transdermal drug delivery systems , 2005, International journal of cosmetic science.

[9]  J. Morais,et al.  Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Y. Barenholz,et al.  Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. , 2005, Molecular pharmaceutics.

[11]  M. Cruz,et al.  The effect of cholate on solubilisation and permeability of simple and protein-loaded phosphatidylcholine/sodium cholate mixed aggregates designed to mediate transdermal delivery of macromolecules. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Fredrik Johansson,et al.  Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  E. Touitou,et al.  Drug delivery across the skin , 2002, Expert opinion on biological therapy.

[14]  A. Schätzlein,et al.  Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. , 2002, Biochimica et biophysica acta.

[15]  G. Cevc,et al.  New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. , 2001, Biochimica et biophysica acta.

[16]  H. Katinger,et al.  Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  V. Muzykantov.  Targeting of superoxide dismutase and catalase to vascular endothelium. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[18]  S. Cuzzocrea,et al.  Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. , 2001, Pharmacological reviews.

[19]  W. Oyen,et al.  Subcutaneous Administration of Superoxide Dismutase Entrapped in Long Circulating Liposomes: In Vivo Fate and Therapeutic Activity in an Inflammation Model , 2000, Pharmaceutical Research.

[20]  W. Oyen,et al.  Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. , 1999, Biochimica et biophysica acta.

[21]  M. Hashida,et al.  Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  M. Shinoda,et al.  ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model , 1998, Inflammation Research.

[23]  J. Queralt,et al.  Effect of Topically Applied Cyclosporin A on Arachidonic Acid (AA)- and Tetradecanoylphorbol Acetate (TPA)-Induced Dermal Inflammation in Mouse Ear , 1997, Inflammation.

[24]  A. Schätzlein,et al.  Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo , 1997 .

[25]  R. Müller-Peddinghaus,et al.  Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[26]  K. Kimura.  Mechanisms of active oxygen species reduction by non-steroidal anti-inflammatory drugs. , 1997, The international journal of biochemistry & cell biology.

[27]  C. Cash.  Are the reactive oxygen-derived species (ROS) interactive properties of the many therapeutic drugs from various categories pertinent to their beneficial effects? , 1997, General pharmacology.

[28]  E. Peltier,et al.  Immunocytochemical study of uptake of exogenous carrier-free copper-zinc superoxide dismutase by peripheral blood lymphocytes. , 1996, Cellular and molecular biology.

[29]  F. Baillet,et al.  Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: an experimental study. , 1996, International journal of radiation oncology, biology, physics.

[30]  A. Schätzlein,et al.  The skin: a pathway for systemic treatment with patches and lipid-based agent carriers , 1996 .

[31]  S. C. Bailey,et al.  Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity. , 1996, Journal of medicinal chemistry.

[32]  F. Walther,et al.  Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits. , 1995, The American journal of physiology.

[33]  J. J. Moreno,et al.  Effects of an anti-inflammatory peptide (antiflammin 2) on cell influx, eicosanoid biosynthesis and oedema formation by arachidonic acid and tetradecanoyl phorbol dermal application. , 1995, Biochemical pharmacology.

[34]  B. Beckermann,et al.  BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. , 1993, The Journal of pharmacology and experimental therapeutics.

[35]  G. Cevc,et al.  Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. , 1992, Biochimica et biophysica acta.

[36]  C. Morris,et al.  Skin inflammation induced by reactive oxygen species (ROS): an in‐vivo model , 1991, The British journal of dermatology.

[37]  D. Smith,et al.  Superoxide dismutase prevents lipid peroxidation in burned patients. , 1990, Burns.

[38]  I W SIZER,et al.  A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. , 1952, The Journal of biological chemistry.

[39]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[40]  G. Wall,et al.  Oral versus topical NSAIDs in rheumatic diseases: a comparison. , 2000, Drugs.

[41]  J. Berthon,et al.  New active ingredient for aging prevention : An amazonian tree extract , 1998 .

[42]  M. Prausnitz.  Reversible skin permeabilization for transdermal delivery of macromolecules. , 1997, Critical reviews in therapeutic drug carrier systems.

[43]  P. Vanelle,et al.  Clinical Pharmacokinetics and Delivery of Bovine Superoxide Dismutase , 1995, Clinical pharmacokinetics.

[44]  K. Hoshi,et al.  Topical application of superoxide dismutase cream. , 1991, Drugs under experimental and clinical research.

[45]  J. Crapo,et al.  Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. , 1984, The Journal of clinical investigation.

[46]  F. Szoka,et al.  Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. , 1980, Biochimica et biophysica acta.